Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD.

We studied 16 patients with stable COPD in a double blind, double dummy, placebo-controlled, within patient study to see if formoterol could be used as a rescue drug. We compared the of onset of bronchodilation obtained with formoterol 12 microg (metered dose corresponding to 9 microg delivered dose) and formoterol 24 microg (metered dose corresponding to 18 microg delivered dose), both delivered via Turbuhaler, with that of salbutamol 400 microg and salbutamol 800 microg delivered via pressurized metered-dose inhaler (pMDI). Patients inhaled single doses of placebo, formoterol and salbutamol on five separate days. FEV1 was measured in baseline condition and 3, 6, 9, 12, 15, 18, 21, 24, 30, 40, 50, and 60 min after inhalation of each treatment. We examined two separate criteria for deciding if a response was greater than that expected by a random variation of the measurement: (1) a rise in FEV1 of at least 15% from the baseline value; (2) an absolute increase in FEV1 of at least 200 ml. Formoterol 12 microg (15.2 min; 95% CI 9.5-21.0) and formoterol 24 microg (15.1 min; 95% CI 8.9-21.2) caused a rise in FEV1 of at least 15% from the baseline value almost rapidly as salbutamol 400 microg (13.6 min; 95% CI 7.1-20.1) and salbutamol 800 microg (14.5 min; 95% CI 7.1-21.9). No significant difference (P=0.982) in onset of action was seen between the four active treatments. According to Criterion 2, the mean time to 200 ml increase in FEV1 was 11.1 min (95% CI: 7.0-15.2) after salbutamol 400 microg, 13.0 min (95% CI: 7.9-18.1) after salbutamol 800 microg, 14.7 min (95% CI: 7.1-22.4) after formoterol 12 microg, and 12.7 min (95% CI: 7.4-18.0) after formoterol 24 microg. Again, there was no significant difference (P= 0.817) between the four active treatments. Formoterol Turbuhaler 12 microg and 24 microg caused bronchodilation as rapidly as salbutamol 400 microg and 800 microg given via pMDI.

[1]  C. Westermann,et al.  Effects of formoterol in apparently poorly reversible chronic obstructive pulmonary disease. , 1999, The European respiratory journal.

[2]  J. Lötvall,et al.  Equivalent bronchodilation with salbutamol given via pMDI or turbuhaler. , 1999, American journal of respiratory and critical care medicine.

[3]  M. Cazzola,et al.  Should long-acting beta 2-agonists be considered an alternative first choice option for the treatment of stable COPD? , 1999, Respiratory medicine.

[4]  M. Cazzola,et al.  Effects of formoterol, salmeterol or oxitropium bromide on airway responses to salbutamol in COPD. , 1998, The European respiratory journal.

[5]  J. Hedner,et al.  Differences in bronchodilating potency of salbutamol in Turbuhaler as compared with a pressurized metered-dose inhaler formulation in patients with reversible airway obstruction. , 1997, The European respiratory journal.

[6]  M. Cazzola,et al.  The use of bronchodilators in stable chronic obstructive pulmonary disease. , 1997, Pulmonary pharmacology & therapeutics.

[7]  R. Pauwels,et al.  The inhalation device influences lung deposition and bronchodilating effect of terbutaline. , 1996, American journal of respiratory and critical care medicine.

[8]  J C Yernault,et al.  Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. , 1995, The European respiratory journal.

[9]  M. Cazzola,et al.  Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. , 1995, Respiratory medicine.

[10]  E. Naline,et al.  Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchus. , 1994, The European respiratory journal.

[11]  M. Cazzola,et al.  Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. , 1994, Pulmonary pharmacology.

[12]  K. Rabe,et al.  Why are long-acting beta-adrenoceptor agonists long-acting? , 1994, The European respiratory journal.

[13]  T. Sandström,et al.  Time course and duration of bronchodilatation with formoterol dry powder in patients with stable asthma. , 1993, Thorax.

[14]  G. Anderson.  Formoterol: pharmacology, molecular basis of agonism, and mechanism of long duration of a highly potent and selective beta 2-adrenoceptor agonist bronchodilator. , 1993, Life sciences.

[15]  H. Hedenström,et al.  Rapid onset of action of inhaled formoterol in asthmatic patients. , 1992, Chest.

[16]  G. Ferngren.  Book ReviewThe Smallpox Story in Words and Pictures The Pasteurization of France , 1989 .

[17]  Buist As.  Standardization of spirometry. , 1987 .